



The First Large-scale Global Survey Comparing Patients and Doctors Perspectives on Treatments for Relapsed/Refractory Multiple Myeloma (RRMM)^{1,a}




1301 PATIENTS



983 HEALTH CARE PROFESSIONALS (HCPs)

7 COUNTRIES^{1,a}

The survey showed differences in patient and HCP treatment priorities^{1,2,b}



These results highlight the importance of **shared decision-making**.¹ **Talking openly with your doctor** can help them **understand your treatment goals** and allows them to **explain your therapeutic options**

The survey showed patients may be unaware of select novel therapies¹



up to **42%** had **never heard of bispecific antibodies (BsAbs)**^d



up to **33%** had **never heard of chimeric antigen receptor (CAR) T-cell therapies**^d



13% remembered being **offered BsAbs**^e



17% remembered being **offered CAR T-cell therapies**^e

Scan to learn more from the UniteMM website



Survey limitations may include¹

- Variable number of respondents per question
- Selection bias for patients who are technologically-literate and/or highly involved in the MM community
- Some respondents not recalling details accurately or not answering some questions
- The results not showing direct cause and effect or capturing cultural differences

^aWeb-based, quantitative survey conducted from March to June 2024 included patients with RRMM, and oncologists with at least 3 patients with MM receiving second-line or later treatment within the last year. Countries included the US, UK, France, Germany, Italy, Spain, and Japan.¹ ^bPatients and HCPs were asked to select their top 3 treatment priorities.¹ ^cEarly-stage RRMM refers to patients having only 1 prior line of therapy.² ^dNot all patients responded to this prompt (N=1,171).¹ ^e720 patients responded to the BsAb prompt and 818 patients responded to the CAR T-cell therapy prompt. Not all surveyed patients were eligible for these therapies.^{1,3}

BsAb, bispecific antibody; CAR, chimeric antigen receptor; HCP, health care professional; MM, multiple myeloma; RRMM, relapsed/refractory multiple myeloma.

1. Ailawadhi S, et al. *Patient Prefer Adherence*. 2025;19:1089-1104. 2. Data on file. Pfizer Inc., New York, NY. 3. Data on file. Pfizer Inc., New York, NY.